ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2759

Prevalence of Comorbidities and Risk Factors of Spondyloarthritis in Latin America: A Comparative Study with the General Population: Data from the Multinational ASAS-Comospa Study

WILSON BAUTISTA-MOLANO1,2, Robert Landewé3, Anna Molto4, Rubén Burgos-Vargas5, José Antonio Maldonado-Cocco6, Rafael Valle-Oñate7 and Désirée van der Heijde8, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology Department, School of Medicine, UMNG / HMC, Bogotá, Colombia, 3Amsterdam Medical Center, Amsterdam, Netherlands, 4Hopital Cochin, Paris Descartes University, Paris, France, 5Rheumatology, Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, 6Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 7Rheumatology Department, School of Medicine, UMNG / HMC, Bogota, Colombia, 8Leiden University Medical Center, Leiden, Netherlands

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Comorbidity, risk assessment and spondylarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  Increased risk of several comorbidities has been reported in spondyloarthritis (SpA). Data and knowledge regarding the prevalence of these comorbidities and risk factors in Latin America are limited. The objective of this study is to determine the prevalence and risk of develop comorbidities as assessed in the ASAS-COMOSPA study in patients with SpA in three Latin American countries, and to compare this prevalence with the information in the general population to determine whether the prevalence and the risk of comorbidities is increased.

Methods:

Data from 390 consecutive patients with SpA enrolled in the international cross-sectional ASAS-COMOSPA study from Argentina, Colombia and Mexico were analyzed. The prevalence (95% CI) standardized by age and gender was estimated for arterial hypertension (AHT), tuberculosis (TB), and malignancies (colon, skin, lung, lymphoma, prostate, cervix and breast). Data from the general population (stratified by gender and age group) were obtained from the CARMELA study for AHT, the Global TB report and the GLOBOCAN project for malignancies. The prevalence in SpA patients was compared with the prevalence. in the general population by calculating the age- and gender-specific categories. A standardized risk ratio (SRR) was calculated for corrected age and gender groups between the SpA patients and the data from the general population. SPSS 22 was used to perform the statistical analyses.

Results:

In total, 64% were male, the mean age was 45 (14.7) years and the disease duration was 7.0 (8.1) years. The most common comorbidities were AHT (25.3%), hypercholesterolemia (21.8%), osteoporosis (9.4%) and gastrointestinal ulcer (7.8%). The prevalence of AHT was 25.3% (95% CI 21.2 to 29.4) and was higher compared with the general population (16.3%, 95% CI 15.4 to 17.2). The AHT risk of patients with SpA was increased 8.8 times compared with the general population The overall prevalence of TB was 3.33% (95% CI 1.8 to 5.7), and was higher compared with the general population (0.03%). The total risk of TB was found to increase 14.6 times than expected to general population. There was no a significantly increased prevalence of malignancies compared with the general population.

Conclusion:

In patients with SpA we observed a higher prevalence and risk for AHT and TB in three Latin American countries than expected from the age-and gender-adjusted general population. A systematic evaluation and screening of these comorbidities and risk factors may help to properly monitor and detect these conditions in SpA patients.


Disclosure: W. BAUTISTA-MOLANO, None; R. Landewé, None; A. Molto, None; R. Burgos-Vargas, Abbvie, Janssen, Pfizer, and UCB, 8; J. A. Maldonado-Cocco, None; R. Valle-Oñate, None; D. van der Heijde, None.

To cite this abstract in AMA style:

BAUTISTA-MOLANO W, Landewé R, Molto A, Burgos-Vargas R, Maldonado-Cocco JA, Valle-Oñate R, van der Heijde D. Prevalence of Comorbidities and Risk Factors of Spondyloarthritis in Latin America: A Comparative Study with the General Population: Data from the Multinational ASAS-Comospa Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/prevalence-of-comorbidities-and-risk-factors-of-spondyloarthritis-in-latin-america-a-comparative-study-with-the-general-population-data-from-the-multinational-asas-comospa-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-comorbidities-and-risk-factors-of-spondyloarthritis-in-latin-america-a-comparative-study-with-the-general-population-data-from-the-multinational-asas-comospa-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology